Obesity Drug Deal: Novo Nordisk will pay China’s Hengrui Pharma $300M upfront and up to $2.6B for rights to HRS-1596, a once-weekly oral GLP-1/GIP dual agonist, with milestones tied to development and commercialization outside China, Hong Kong, Macao and Taiwan—another bet as Novo tries to defend its obesity franchise. US–China Summit Fallout for Taiwan: Taiwan’s defense minister says existing U.S. arms sales remain unchanged and talks continue, but a record $14B package is still stalled amid mounting concern Trump could pause sales; Taiwan also says F-16V deliveries are progressing. Solar Tech Leap: Researchers report tandem all-perovskite triple-junction solar cells topping 30% efficiency, while Taiwan-based teams push perovskite/silicon tandems toward 34% in lab results—useful for local clean-energy manufacturing ambitions. AI Infrastructure Demand: A market roundup highlights how AI growth is pulling on power, chips, data centers and cloud services, with investors watching the industrial supply chain behind AI compute. Semiconductor/PCB Supply Chain: Amazon is taking part in a private placement by Taiwan PCB maker Gold Circuit Electronics, signaling continued hyperscale demand for AI-server interconnects. Taiwan in the News Cycle: Taiwan’s Taiex slips as global markets react to bond-yield moves and oil uncertainty.